Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: J Biophotonics. 2018 Sep 25;12(4):e201800170. doi: 10.1002/jbio.201800170

Figure 2. GDP microcapsules maximize the fluorescence of genipin while preserving cell viability and function.

Figure 2.

a, Eschematic depiction showing GDP microcapsules and all the intermediate control groups assayed in the study. b, Reaction kinetics of genipin fluorescence development (Em: 590 nm; Ex: 630 nm) (n = 4 samples per group). Error bars, mean ±SD. c, Fluorescence intensity of microcapsules 96 h after encapsulation (n = 4 samples per group). Error bars, mean ±SD. **, p < 0.01; ***, p < 0.001; One-way ANOVA with Tamhane multiple comparison correction. d, Confocal fluorescence analysis of microcapsules. From left to right: representative confocal fluorescence micrographs, profile lines and 3D surface plots of the fluorescence signal distribution and intensity from the equatorial section of microcapsules. Scale bar, 200 µm. e, Metabolic activity of encapsulated D1-MSC-hEPO cells (n = 4 samples per group) 96 h after encapsulation. Error bars, mean ±SD. N.S. specifies non-significant differences against the AP group, p > 0.05; One-way ANOVA with Bonferroni multiple comparison correction. Mann–Whitney U test was used with APP group (non-normal distribution). f, Representative confocal fluorescence image of cells encapsulated in GDP microcapsules and probed with LIVE/DEAD viability kit (Green, living cells; Red, dead cells) 14 days after encapsulation. g, hEPO secretion of immobilized D1-MSC-hEPO cells (n = 3 samples per group in duplicate) 96 h after encapsulation. Error bars, mean ±SD. N.S. indicates non-significant differences against the AP group, p > 0.05; One-way ANOVA with Bonferroni multiple comparison correction. FL, fluorescence.